100.00% -8.28

Cybin Inc (CYBN)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Cybin Inc Borsa (CYBN) Ultime notizie

Cybin Inc (CYBN)

Cybin Inc Borsa (CYBN) Ultime notizie

Robert Langer, who helped found Moderna, joins Helus Pharma board - Stock Titan

How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st

[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan

symbol__ Stock Quote Price and Forecast - CNN

Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade) (NASDAQ:HELP) - Seeking Alpha

Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money

Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN

Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India

Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN

Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks

Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan

Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan

Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus

Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions - The Manila Times

White House psychedelics push intersects with Helus Phase 3 depression drug - Stock Titan

Helus Pharma Announces CEO Changes Effective April 20, 2026 - marketscreener.com

Cybin Inc. Common Stock (HELP) - Minichart

Cybin Insider Ups Holding By 105% During Year - Yahoo Finance

HELP Options Chain — NASDAQ:HELP - TradingView

Millennium Management LLC Acquires Additional Shares in Helus Ph - GuruFocus

Psychedelic Stocks Tracker - Psychedelic Alpha

Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs - Investing News Network

Helus Pharma Taps Neuroscience Veteran Ken Kramer to Lead Medical Affairs - TipRanks

Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN

HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Aug PostEarnings: What hedge funds are buying Cybin Inc2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn

Cybin (NASDAQ:HELP) Now Covered by TD Cowen - MarketBeat

Top Cybin (HELP) Competitors 2026 - MarketBeat

HELP: Cybin Inc.Brokerage Recommendations Chart - Zacks Investment Research

Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN

Millennium Group (CYBN) reports 2.51M shares, 5.0% stake - Stock Titan

Rate Cut: Will Cybin Inc stock recover after earningsRisk Management & Technical Pattern Based Signals - baoquankhu1.vn

Can Cybin (HELP) Stock Beat Estimates | Price at $5.33, Up 1.52%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai

Aug Decliners: Does Cybin Inc stock have upside surprise potential2026 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn

Total non-current assets of Cybin, Inc. – NEO:HELP - TradingView — Track All Markets

Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au

HELP Should I Buy - Intellectia AI

HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill

Trend Recap: Is Cybin Inc on track to beat earningsTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn

Guidance Update: Can Cybin Inc be the next market leader2026 Analyst Calls & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

Simile a CYBN